Omeros Corporation $OMER Shares Sold by Corient Private Wealth LP

Corient Private Wealth LP cut its stake in shares of Omeros Corporation (NASDAQ:OMER - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 659,730 shares of the biopharmaceutical company's stock after selling 141,681 shares during the period. Corient Private Wealth LP owned approximately 0.91% of Omeros worth $6,274,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Omeros during the 2nd quarter valued at $57,484,000. Bank of New York Mellon Corp acquired a new stake in shares of Omeros during the second quarter worth approximately $1,864,000. Bank of America Corp DE bought a new stake in shares of Omeros in the second quarter worth $1,846,000. Ancora Advisors LLC acquired a new position in Omeros during the 2nd quarter worth $1,605,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Omeros by 85.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock worth $1,897,000 after purchasing an additional 82,646 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Insider Buying and Selling at Omeros

In other Omeros news, Director Thomas J. Cable sold 15,000 shares of the firm's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the transaction, the director directly owned 35,067 shares in the company, valued at $646,986.15. This trade represents a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arnold C. Hanish sold 10,000 shares of the company's stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the director directly owned 5,000 shares of the company's stock, valued at approximately $94,750. This represents a 66.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 105,906 shares of company stock worth $1,989,705 over the last quarter. Company insiders own 10.50% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on OMER. Wall Street Zen raised Omeros from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. HC Wainwright reiterated a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research lowered Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Cantor Fitzgerald raised Omeros from a "neutral" rating to an "overweight" rating and set a $22.00 target price on the stock in a research note on Tuesday, September 22nd. Finally, Weiss Ratings cut Omeros from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.00.

View Our Latest Research Report on OMER

Omeros Stock Down 0.3%

Shares of OMER traded down $0.05 during midday trading on Tuesday, reaching $19.38. 392,591 shares of the stock were exchanged, compared to its average volume of 1,687,282. The company has a market cap of $1.40 billion, a price-to-earnings ratio of 15.14 and a beta of 2.60. Omeros Corporation has a 12-month low of $4.05 and a 12-month high of $21.24. The firm has a 50 day simple moving average of $16.40 and a 200-day simple moving average of $13.11.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Research analysts expect that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation (NASDAQ:OMER - Free Report) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.